Biotechnology News and Research

RSS

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.

11 Mar 2014

Genetic basis of hereditary disease causes severe brain atrophy in Jews of Moroccan ancestry

Ben-Gurion University of the Negev (BGU) researchers have unraveled the genetic basis of a hereditary disease that causes severe brain atrophy, mental retardation and epilepsy in Jews of Moroccan ancestry, according to a study published this week online in the Journal of Medical Genetics.

11 Mar 2014

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Illumina, Inc. and WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.

From Illumina, Inc. 10 Mar 2014

Clinical Network Services launches new office near London

Clinical Network Services (CNS) an integrated product development company based in Australia and New Zealand providing broad services in the planning, implementation and delivery of preclinical, Phase 1 and 2 trials, today announced that it has launched a new office near London headed by Paul Cronin who joins as UK Director and Director, Business Development.

10 Mar 2014

Nordion generates $70.8 million in revenue for first quarter of fiscal 2014

Nordion Inc., a leading provider of products and services to the global health science market, today reported results for the first quarter of fiscal 2014.

7 Mar 2014

Researchers awarded $26M NIH grant to advance treatments for Ebola and Marburg

The University of Texas Medical Branch at Galveston, Profectus Biosciences, Tekmira Pharmaceuticals and the Vanderbilt University Medical Center have been awarded up to $26 million to advance treatments of the highly lethal hemorrhagic fever viruses Ebola and Marburg.

6 Mar 2014

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals.

6 Mar 2014

Bio-Rad announces release of beta version of the USP Spectral Library

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the release of beta version of USP Spectral Library™ powered by Bio Rad's KnowItAll® software technology platform for spectral analysis, identification, search, data management, and reporting.

From Bio-Rad Laboratories 5 Mar 2014

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai Co., Ltd. and Biogen Idec announced today that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401.

5 Mar 2014

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

Researchers at Norris Cotton Cancer Center have found an antibody that may be used in future treatments for recurrent small-cell lung cancer, which currently has no effective therapy.

5 Mar 2014

AJT describes novel approach to long-term tolerance in organ transplantation

REGiMMUNE Corporation announced that the American Journal of Transplantation (AJT) has published its paper that describes a novel approach to long-term tolerance in organ transplantation with continuous administration of immune suppressants.

4 Mar 2014

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.

4 Mar 2014

Microgravity may suppress tumors, study reveals

In space, things don't always behave the way we expect them to. In the case of cancer, researchers have found that this is a good thing: some tumors seem to be much less aggressive in the microgravity environment of space compared to their behavior on Earth. This observation, reported in research published in February by the FASEB Journal, could help scientists understand the mechanism involved and develop drugs targeting tumors that don't respond to current treatments. This work is the latest in a large body of evidence on how space exploration benefits those of us on Earth.

4 Mar 2014

Neuroscientists unlock a piece of puzzle in fight against Lou Gehrig's disease

Keck School of Medicine of USC neuroscientists have unlocked a piece of the puzzle in the fight against Lou Gehrig's disease, a debilitating neurological disorder that robs people of their motor skills.

4 Mar 2014

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

4 Mar 2014

Dendreon plans to make PROVENGE available in Europe

Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.

3 Mar 2014

Indonesia's commitment, investment in eliminating NTDs could lift millions of people out of poverty

The control and elimination of neglected tropical diseases (NTDs) is one of the most cost-effective ways Indonesia can sustain economic growth and reduce inequality, said scientists today in an analysis published in PLOS Neglected Tropical Diseases.

3 Mar 2014

Therapeutic hypothermia may not be effective in all patients who suffered heart attack, says study

Whole body cooling in comatose patients who have suffered a heart attack can limit the damage to brain tissue caused by the restoration of blood flow and oxygen.

26 Feb 2014

Prothelia and University of Nevada, Reno enter into agreements with Alexion for development of Laminin-111

Prothelia Incorporated (Prothelia) and University of Nevada, Reno announce that they have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient congenital muscular dystrophy (MDC1A), a life-threatening, ultra-rare disease caused by a genetic deficiency of the Laminin-211 protein.

26 Feb 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Biotechnology News and Research

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Genetic basis of hereditary disease causes severe brain atrophy in Jews of Moroccan ancestry

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Clinical Network Services launches new office near London

Nordion generates $70.8 million in revenue for first quarter of fiscal 2014

Researchers awarded $26M NIH grant to advance treatments for Ebola and Marburg

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Bio-Rad announces release of beta version of the USP Spectral Library

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Researchers find antibody that may be used in future treatments for recurrent small-cell lung cancer

AJT describes novel approach to long-term tolerance in organ transplantation

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Microgravity may suppress tumors, study reveals

Neuroscientists unlock a piece of puzzle in fight against Lou Gehrig's disease

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Dendreon plans to make PROVENGE available in Europe

Indonesia's commitment, investment in eliminating NTDs could lift millions of people out of poverty

Therapeutic hypothermia may not be effective in all patients who suffered heart attack, says study

Prothelia and University of Nevada, Reno enter into agreements with Alexion for development of Laminin-111

FDA approves KALYDECO for people with cystic fibrosis

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News